Singh JA, Saag KG, Bridges SLJ, Akl EA, Bannuru RR, Sullivan MC, Vaysbrot E, McNaughton C, Osani M, Shmerling RH, Curtis JR, Furst DE, Parks D, Kavanaugh A, O'Dell J, King C, Leong A, Matteson EL, Schousboe JT, Drevlow B, Ginsberg S, Grober J, St Clair EW, Tindall E, Miller AS, McAlindon T (2016) 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 68:1–25
Article
Google Scholar
Smolen JS, Landewé R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, Nam J, Ramiro S, Voshaar M, van Vollenhoven R, Aletaha D, Aringer M, Boers M, Buckley CD, Buttgereit F, Bykerk V, Cardiel M, Combe B, Cutolo M, van Eijk-Hustings Y, Emery P, Finckh A, Gabay C, Gomez-Reino J, Gossec L, Gottenberg JE, Hazes JM, Huizinga T, Jani M, Karateev D, Kouloumas M, Kvien T, Li Z, Mariette X, McInnes I, Mysler E, Nash P, Pavelka K, Poor G, Richez C, van Riel P, Rubbert-Roth A, Saag K, da Silva J, Stamm T, Takeuchi T, Westhovens R, de Wit M, van der Heijde D (2017) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 76:960–977. https://doi.org/10.1136/annrheumdis-2016-210715
Article
Google Scholar
Kiely PD (2016) Biologic efficacy optimization—a step towards personalized medicine. Rheumatology (Oxford) 55:780–788
Article
CAS
Google Scholar
Genovese MC, Schiff M, Luggen M, Becker JC, Aranda R, Teng J, Li T, Schmidely N, Le BM, Dougados M (2008) Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy. Ann Rheum Dis 67:547–554
Article
CAS
PubMed
Google Scholar
Kremer JM, Genant HK, Moreland LW, Russell AS, Emery P, Abud-Mendoza C, Szechinski J, Li T, Teng J, Becker JC, Westhovens R (2008) Results of a two-year follow up study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate. Arthritis Rheum 58:953–963
Article
CAS
PubMed
Google Scholar
Westhovens R, Kremer J, Emery P, Russell A, Alten R, Barre E, Dougados M (2014) Long-term safety and efficacy of abatacept in patients with rheumatoid arthritis and an inadequate response to methotrexate: a 7-year extended study. Clin Exp Rheumatol 32:553–562
PubMed
Google Scholar
Yoshida K, Radner H, Kavanaugh A, Sung YK, Bae SC, Kishimoto M, Matsui K, Okada M, Tohma S, Weinblatt ME, Solomon DH (2013) Use of data from multiple registries in studying biologic discontinuation: challenges and opportunities. Clin Exp Rheumatol 31:S28–S32
PubMed
PubMed Central
Google Scholar
Curtis JR, Jain A, Askling J, Bridges SL Jr, Carmona L, Dixon W, Finckh A, Hyrich K, Greenberg JD, Kremer J, Listing J, Michaud K, Mikuls T, Shadick N, Solomon DH, Weinblatt ME, Wolfe F, Zink A (2010) A comparison of patient characteristics and outcomes in selected European and US rheumatoid arthritis registries. Semin Arthritis Rheum 40:2–14
Article
PubMed
PubMed Central
Google Scholar
Vashisht P, Sayles H, Cannella AC, Mikuls TR, Michaud K (2016) Generalizability of patients with rheumatoid arthritis in biologic agent clinical trials. Arthritis Care Res (Hoboken ) 68:1478–1488
Article
CAS
Google Scholar
Orencia 250 mg powder for concentrate for solution for infusion. (2017). http://www.medicines.org.uk/emc/medicine/19714/SPC/. Accessed May 21, 2018
Product monograph: Orencia (abatacept). (2015). http://www.bmscanada.ca/static/products/en/pm_pdf/ORENCIA_EN_PM.pdf. Accessed October 10, 2018
Cutolo M, Sulli A, Paolino S, Pizzorni C (2016) CTLA-4 blockade in the treatment of rheumatoid arthritis: an update. Expert Rev Clin Immunol 12:417–425
Article
CAS
PubMed
Google Scholar
Nüßlein H, Alten R, Galeazzi M, Lorenz HM, Boumpas D, Nurmohamed MT, Bensen WG, Burmester GR, Peter HH, Rainer F, Pavelka K, Chartier M, Poncet C, Rauch C, Le Bars M (2014) Real-world effectiveness of abatacept for rheumatoid arthritis treatment in European and Canadian populations: a 6-month interim analysis of the 2-year, observational, prospective ACTION study. BMC Musculoskelet Disord 15(14)
Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheumatol 31:315–324
Article
CAS
Google Scholar
World Medical Association Declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects (1997) JAMA 277:925–926
Article
Google Scholar
ICH Harmonised Tripartite Guideline Guideline for good clinical practice (2001). J Postgrad Med 47:199–203
Olsen J (2007) Good Epidemiological Practice (GEP): IEA Guidelines for Proper Conduct in Epidemiological Research
Alten R, Mariette X, Lorenz HM, Galeazzi M, Cantagrel A, Nusslein HG, Chartier M, Elbez Y, Rauch C, Le Bars M (2017) Real-world predictors of 12-month intravenous abatacept retention in patients with rheumatoid arthritis in the ACTION observational study. RMD Open 3:e000538. https://doi.org/10.1136/rmdopen-2017-000538
Article
PubMed
PubMed Central
Google Scholar
Fransen J, van Riel PL (2009) The disease activity score and the EULAR response criteria. Rheum Dis Clin N Am 35:745–757
Article
Google Scholar
Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LH, Funovits J, Aletaha D, Allaart CF, Bathon J, Bombardieri S, Brooks P, Brown A, Matucci-Cerinic M, Choi H, Combe B, de Wit M, Dougados M, Emery P, Furst D, Gomez-Reino J, Hawker G, Keystone E, Khanna D, Kirwan J, Kvien TK, Landewe R, Listing J, Michaud K, Martin-Mola E, Montie P, Pincus T, Richards P, Siegel JN, Simon LS, Sokka T, Strand V, Tugwell P, Tyndall A, van der Heijde D, Verstappen S, White B, Wolfe F, Zink A, Boers M (2011) American College of Rheumatology/European league against rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis 70:404–413
Article
PubMed
Google Scholar
Finckh A, Gomez-Reino J, Iannone F, Lie E, Canhao H, Pavelka K, Turesson C, Mariette X, Gottenberg JE, Hetland M, ABA oboP-E-Ro (2014) The impact of DMARD co-therapy on abatacept effectiveness in rheumatoid arthritis patients. A pan-European analysis of RA registries. Ann Rheum Dis 73(Suppl2):FRI0298. https://doi.org/10.1136/annrheumdis-2014-eular.3004
Article
Google Scholar
Finckh A, Neto D, Iannone F, Loza E, Lie E, van Riel P, Hetland ML, Pavelka K, Gottenberg JE, Canhão H, Mariette X, Turesson C (2015) The impact of patient heterogeneity and socio-economic factors on abatacept retention in rheumatoid arthritis across nine European countries. RMD Open 1:e000040
Article
CAS
PubMed
PubMed Central
Google Scholar
De Keyser F, Hoffman I, Durez P, Kaiser MJ, Westhovens R (2014) Longterm followup of rituximab therapy in patients with rheumatoid arthritis: results from the Belgian MabThera in Rheumatoid Arthritis registry. J Rheumatol 41:1761–1765
Article
CAS
PubMed
Google Scholar
Forsblad-d'Elia H, Bengtsson K, Kristensen LE, Jacobsson LTH (2012) Drug survival, efficacy and predictors for survival on tocilizumab in real-life patients with rheumatoid arthritis; results from the Swedish Biologics Register. Arthritis Rheumatol 64:S201
Google Scholar
Greenberg JD, Reed G, Decktor D, Harrold L, Furst D, Gibofsky A, Dehoratius R, Kishimoto M, Kremer JM (2012) A comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registry. Ann Rheum Dis 71:1134–1142
Article
CAS
PubMed
Google Scholar
Rotar Z, Hocevar A, Rebolj KA, Praprotnik S, Tomsic M (2015) Retention of the second-line biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis failing one tumor necrosis factor alpha inhibitor: data from the BioRx.si registry. Clin Rheumatol 34:1787–1793
Article
PubMed
Google Scholar
Maxwell LJ, Singh JA (2010) Abatacept for rheumatoid arthritis: a Cochrane systematic review. J Rheumatol 37:234–245
Article
CAS
PubMed
Google Scholar
Schiff M, Poncet C, Le BM (2010) Efficacy and safety of abatacept therapy for rheumatoid arthritis in routine clinical practice. Int J Clin Rheumatol 5:581–591
Article
CAS
Google Scholar
Weinblatt ME, Moreland LW, Westhovens R, Cohen RB, Kelly SM, Khan N, Pappu R, Delaet I, Luo A, Gujrathi S, Hochberg MC (2013) Safety of abatacept administered intravenously in treatment of rheumatoid arthritis: integrated analyses of up to 8 years of treatment from the abatacept clinical trial program. J Rheumatol 40:787–797
Article
CAS
PubMed
Google Scholar
Alten R, Nüßlein H, Galeazzi M, Lorenz HM, Mariette X, Cantagrel A, Chartier M, Elbez Y, Rauch C, Le Bars M (2016) Do predictors of IV abatacept retention depend on the line of rheumatoid arthritis treatmen: 12-month interim analysis of the observational, prospective ACTION study. Ann Rheum Dis 75:202
Article
Google Scholar
Nüßlein HG, Alten R, Galeazzi M, Lorenz HM, Nurmohamed MT, Bensen WG, Burmester GR, Peter HH, Pavelka K, Chartier M, Poncet C, Rauch C, Le Bars M (2015) Prognostic factors for abatacept retention in patients who received at least one prior biologic agent: an interim analysis from the observational, prospective ACTION study. BMC Musculoskelet Disord 16:176. https://doi.org/10.1186/s12891-015-0636-9
Article
CAS
PubMed
PubMed Central
Google Scholar
Nüßlein HG, Alten R, Galeazzi M, Lorenz HM, Nurmohamed MT, Bensen WG, Burmester GR, Peter HH, Peichl P, Pavelka K, Chartier M, Poncet C, Rauch C, Le BM (2016) Efficacy and prognostic factors of treatment retention with intravenous abatacept for rheumatoid arthritis: 24-month results from an international, prospective, real-world study. Clin Exp Rheumatol 34:489–499
PubMed
Google Scholar
Gabay CRM, Scherer A, Finckh A (2015) Effectiveness of biologic DMARDs in monotherapy versus in combination with synthetic DMARDs in rheumatoid arthritis: data from the Swiss Clinical Quality Management Registry. Rheumatology (Oxford) 54:1664–1672. https://doi.org/10.1093/rheumatology/kev019
Article
CAS
Google Scholar
Gottenberg JE, Courvoisier DS, Hernandez MV, Iannone F, Lie E, Canhao H, Pavelka K, Hetland ML, Turesson C, Mariette X, Finckh A (2016) Brief report: association of rheumatoid factor and anti-citrullinated protein antibody positivity with better effectiveness of abatacept: results from the pan-European registry analysis. Arthritis Rheumatol 68:1346–1352
Article
CAS
PubMed
Google Scholar
Huizinga TWJ, Connolly SE, Johnsen A, Zhu J, Furst DE, Bykerk VP, Burmester GR, Combe BG, Wong DA, Trouw LA, Toes REM, Emery P (2015) Effect of anti-cyclic citrullinated peptide 2 immunoglobulin M serostatus on efficacy outcomes following treatment with abatacept plus methotrexate in the AVERT trial. Ann Rheum Dis 74(Suppl 2):234–235
Article
PubMed
Google Scholar
Sokolove J, Schiff M, Fleischmann R, Weinblatt ME, Connolly SE, Johnsen A, Zhu J, Maldonado MA, Patel S, Robinson WH (2016) Impact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2-year results from the AMPLE trial. Ann Rheum Dis 75:709–714
Article
CAS
PubMed
Google Scholar
Harrold LR, Litman HJ, Connolly SE, Kelly S, Hua W, Alemao E, Rosenblatt L, Rebello S, Kremer JM (2018) Effect of anticitrullinated protein antibody status on response to abatacept or antitumor necrosis factor-alpha therapy in patients with rheumatoid arthritis: a US National Observational Study. J Rheumatol 45:32–39. https://doi.org/10.3899/jrheum.170007
Article
CAS
PubMed
Google Scholar
Bozec A, Luo Y, Ngdahl C et al. (2018) Abatacept blocks anti-citrullinated protein antibody and rheumatoid factor mediated cytokine production in human macrophages in IDO-dependent manner. Arthritis Res Ther 20. https://doi.org/10.1093/rheumatology/ket224
Ranganath VK, Maranian P, Elashoff DA, Woodworth T, Khanna D, Hahn T, Sarkisian C, Kremer JM, Furst DE, Paulus HE (2013) Comorbidities are associated with poorer outcomes in community patients with rheumatoid arthritis. Rheumatology (Oxford) 52:1809–1817
Article
Google Scholar
McWilliams DF, Walsh DA (2016) Factors predicting pain and early discontinuation of tumour necrosis factor-a-inhibitors in people with rheumatoid arthritis: results from the British society for rheumatology biologics register. BMC Musculoskeletal Disorders. https://doi.org/10.1186/s12891-12016-11192-12897 doi:27515300
Kang EH, Yinzhu J, Brill G, Lewey J, Patorno E, Desai RJ, Kim SC (2018) Comparative cardiovascular risk of abatacept and tumor necrosis factor inhibitors in patients with rheumatoid arthritis with and without diabetes mellitus: a multidatabase cohort study. J Am Heart Assoc 7:e007393. https://doi.org/10.1161/JAHA.117.007393
Lee J, Mason R, Martin L, Barnabe C (2014) Biologic therapy response and drug survival for females compared to males with rheumatoid arthritis: a cohort study. Rheumatol Int 34:1449–1453
Article
PubMed
Google Scholar
Alten R, Nüßlein H, Galeazzi M, Lorenz H-M, Mariette X, Cantagrel A, Chartier M, Desachy G, Poncet C, Rauch C, Le Bars M (2015) Body mass index does not influence the efficacy of abatacept in patients with RA who are biologic naive: 6-month results from a real-world, international prospective study. Arthritis Rheumatol 67(suppl 10):abstract 553. https://acrabstracts.org/abstract/body-mass-index-does-not-influence-the-efficacy-of-abatacept-in-patientswith-ra-who-are-biologic-naive-6-month-results-from-a-real-world-international-prospective-study/
Alten R, Nusslein HG, Mariette X, Galeazzi M, Lorenz HM, Cantagrel A, Chartier M, Poncet C, Rauch C, Le Bars M (2017) Baseline autoantibodies preferentially impact abatacept efficacy in patients with rheumatoid arthritis who are biologic naive: 6-month results from a real-world, international, prospective study. RMD Open 3:e000345. https://doi.org/10.1136/rmdopen-2016-000345
Article
PubMed
PubMed Central
Google Scholar
Harigai M, Ishiguro N, Inokuma S, Mimori T, Ryu J, Takei S, Tanaka Y, Takasaki Y, Yamanaka H, Watanabe M, Tamada H, Koike T (2016) Postmarketing surveillance of the safety and effectiveness of abatacept in Japanese patients with rheumatoid arthritis. Mod Rheumatol 8:1–8
Google Scholar